GlassScriptPhysician profile
Nicholas Richard Snavely
NPI 1801099460
$3,944.00
in general payments reported to CMS, 2019-2025
31 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.92 · 2020: $166 · 2021: $573 · 2022: $512 · 2023: $876 · 2024: $1,127 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.50 | 2021-2025 | Rinvoq, Skyrizi |
| Kerecis Limited | $448.25 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Janssen Biotech, INC. | $425.90 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $259.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $217.87 | 2023-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $194.56 | 2020-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $157.38 | 2020-2025 | Otezla, Otezla |
| Misonix INC | $150.74 | 2021 | |
| Incyte Corporation | $131.04 | 2022-2025 | Opzelura |
| Pfizer INC. | $123.51 | 2023-2025 | |
| Allergan, INC. | $113.12 | 2020 | |
| Organogenesis INC. | $94.69 | 2023-2024 | Puraply |
| Genzyme Corporation | $91.82 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $88.44 | 2021-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $83.92 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $58.54 | 2024-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.74 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $40.91 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $39.81 | 2021 | |
| Elekta, INC. | $39.01 | 2025 | Flexitron Hdr |
| Mimedx Group, INC. | $32.49 | 2024 | |
| Genentech USA, INC. | $27.02 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.25 | 2024 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $21.31 | 2024 | Sotyktu |
| Ucb, INC. | $18.27 | 2024 | Bimzelx |
| Smith+Nephew, INC. | $17.52 | 2025 | Collagenase Santyl |
| Krystal Biotech INC | $16.36 | 2023 | Vyjuvek |
| Galderma Laboratories, L.P. | $16.13 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $15.67 | 2023 | Tovet (Emollient Formulation) |
| Strata Skin Sciences, INC. | $15.35 | 2024 | Xtrac |
| Medline Industries LP | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Snavely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.